32.9 F
New York
Thursday, January 20, 2022

Abbott’s [NYSE: ABT] BinaxNOW Gets FDA Emergency Use Authorization

Must read

Abbott Laboratories [NYSE: ABT] has made an announcement that its BinaxNOW™ COVID-19 Ag Self-Test for recognition of COVID-19 infection has got the EUA from FDA. This new identification option will enable sufferers with or without symptoms to gain access to this test without a prescription. This test will be very simple for the victims who have never tested themselves against the novel virus.

The BinaxNOW COVID-19 Ag Self-Test is also useful for children as young as two years old when samples are collected by a grownup and for all individuals in the age of 15 years or more. This test will provide an opportunity to everyone in the US to use the most widely examined and most commonly used rapid antigen test.

The benefit of Serial Testing with BinaxNOW

BinaxNOW will provide a chance to individuals to know whether they got the virus or not. One more benefit of this test is that it is the least expensive. It allows people to test themselves on a regular basis who were frequently exposed to the virus. Furthermore, this test will also provide the individual an opportunity to get their test result in 15 minutes. The rapid testing will allow individuals to know whether they are positive or not and get themselves isolated.

Availability of BinaxNOW™ COVID-19 Ag Self-Test

Abbott will commence delivery to major food, drug, and mass dealer stores in the next few weeks. The firm has also disclosed that the test will also be accessible to people through their online store websites. Additionally, ABT has also provided the benefit to the people that they will get the test in a two-count box to meet serial regular testing needs.

ABT has rolled out the BinaxNOW professional test all over the country in August 2020. Furthermore, it will increase the manufacturing capacity at its new U.S. production facilities to manufacture 50 million tests per month. Previously, The U.S. HHS has bought the first 150 million tests of the firm.

More articles

Latest article